血小板/淋巴细胞在贝伐珠单抗联合化疗治疗晚期非小细胞肺癌中的预测价值  

Predictive value of PLR in treatment of Beacizumab with chemotherapy for advanced NSCLC

作　　者：陈忆玲 周光华[1] 郝娟 Chen Yi-ling;Zhou Guang-hua;Hao Juan(The Second Affiliared Hospital of Hunan Normal University,921th Hospital of PLA,Changsha 410003,China)

机构地区：[1]湖南师范大学第二附属医院,中国人民解放军联勤保障部队第九二一医院,长沙410003

出　　处：《湖南师范大学学报（医学版）》2021年第2期101-105,共5页Journal of Hunan Normal University(Medical Sciences)

摘　　要：目的:探讨贝伐珠单抗治疗晚期非小细胞肺癌(NSCLC)时,治疗前血小板/淋巴细胞(PLR)对其疗效和预后的预测作用。方法:选取晚期NSCLC患者140例,贝伐珠单抗+化疗治疗者70例为A组,单纯化疗者70例为B组,于治疗前计算PLR,并使用SPSS 22.0中的ROC曲线进行统计分析,确定PLR的界值,分析PLR与两组患者临床特征的关系,通过Kaplan-Meier法分析患者的生存,应用COX风险回归模型进行多因素分析。结果:应用ROC曲线选取PLR=174为最佳界值,A组患者中低PLR组的PFS优于高PLR组(19个月vs 9个月),低PLR组的OS优于高PLR组(28个月vs 19个月);B组患者中低PLR组的PFS优于高PLR组(11个月vs 9个月),低PLR组的OS优于高PLR组(26个月vs 19个月);全组患者中,低PLR组患者中贝伐珠单抗+化疗组的PFS优于单纯化疗组(19个月vs 11个月)。COX风险回归分析示,PLR是A组晚期NSCLC患者PFS的独立预后因素,但不是OS的独立预后因素。结论:PLR可用来预测贝伐珠单抗治疗晚期非小细胞肺癌(NSCLC)患者的疗效和预后。Objective To explore the predictive effect of platelet-to-lymphocyte ratio(PLR)before treatment on the efficacy and prognosis when discussing the treatment of Bevacizumab in mutated advanced non-small cell lung cancer(NSCLC).Methods We selected 140 patients with advanced NSCLC in our hospital.Among them,70 patients who used Bevacizumab with chemotherapy were in group A,while 70 patients who used chemotherapy alone were in group B.We calculated PLR before treatment,and used the ROC curve in SPSS 22.0 for statistical analysis to determine the boundary value of PLR.Then,analyzing the relationship between PLR and the clinical characteristics of the two groups of patients.The survival of patients were evaluated with Kaplan-Meier analysis respectively and applying COX risk regression model Perform multi-factor analysis.Results ROC curve analysis showed that PLR=174 was optimal cut-off value.In group A,the PFS of patients with low PLR was higher than that of high PLR(19 months vs 9 months),the OS with low PLR was higher than that of high PLR(28months vs 19 months);In group B,the PFS of patients with low PLR was higher than that of high PLR(11months vs 9 months),the OS with low PLR was higher than that of high PLR(26months vs 19 months);In the whole group of patients,the PFS of low PLR patients with chemotherapy with bevacizumab group was higher than that of chemotherapy-alone group(19months vs 11 months).Cox regression analysis revealed that,PLR were independent risk factors for the PFS of patients with advanced NSCLC in group A,but weren’t independent risk factors for the OS.Conclusion PLR can be used to predict the efficacy and prognosis of treatment of Bevacizumab in patients with advanced non-small cell lung cancer(NSCLC).

关 键 词：非小细胞肺癌 贝伐珠单抗 血小板与淋巴细胞比值 预后预测 

分 类 号：R734.2[医药卫生—肿瘤]